- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02177825
Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
Phase II Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
This phase II trial will test the hypothesis that inhibition of c-kit signalling pathways in pediatric patients with Neurofibromatosis Type I(NF-1) and progressing plexiform neurofibroma will result in objective reduction and/or inhibition of plexiform neurofibromas progression.
This will be a Phase II study of imatinib mesylate given orally. Patients with stable or responding disease may receive the drug for a period not exceeding one year.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Clinical objectives
- Demonstrate the clinical benefit of imatinib in a pediatric patient population with progressing and metabolically active plexiform neurofibromas (NF)
- Demonstrate the need or not to pursue treatment for more than a year in responders to imatinib
Biological studies objectives
- Identify biological markers of plexiform neurofibroma progression and response to treatment
- Identify biological markers of mast cell responses to imatinib, given that mast cells are required for tumorigenesis and are a target for imatinib
Imaging studies objectives
Using 18-Fluorodeoxyglucose-positron Emission Tomography (FDG PET/CT):
- Identify imaging characteristics of progressing plexiform neurofibromas
- Assess the role of F18-FDG PET/CT in comparison with CT/MRI to evaluate response to imatinib ¸
Pharmacological study
- Evaluate trough plasma levels of imatinib and its active metabolite (NDMIL N-desmethyl imatinib) achieved in this pediatric population
- Identify potential correlation between imatinib (and NDMI) trough levels achieved and clinical response
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- CHU Sainte-Justine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age Greater than or equal to 2 years and up to 21 years of age at time of study enrolment
- Diagnosis Patients with NF1 and an inoperable plexiform NFs that has the potential to cause significant morbidity.
Patients must have measurable disease by magnetic resonance imaging (MRI) and progressive plexiform neurofibroma(s) with or without clinical symptoms.
- Patients must have a recent FDG-PET scan imaging study done in the last 3 months before being offered participation to the study
- Surgery/Residual disease: Patients are only eligible if complete tumor resection is not feasible, or if a patient with a surgical option refuses surgery. Evidence of recurrent or progressive disease is NOT necessary. Patients must be at least 21 days from surgery, if performed, prior to receiving their first dose of study drug
- Performance level Patients must have a Karnofsky of > 70% or Lansky of >50% and a life expectancy of > 6 months.
- Previous use of imatinib is permitted if there was no progressive disease during treatment.
- Prior therapy Patients must be at least 28 days without any treatment before enrolment in this study.
- Patient is free of another primary malignancy except if the other primary malignancy neither currently clinically significant nor requiring active intervention.
Organ function requirement
- Creatinine < 1.5 x upper limit of normal (ULN)
- Total bilirubin < 1.5 x ULN and SGOT and SGPT < 2.5 x ULN
- ANC > 1.5 x 109/L and Platelets > 100 x 109/L
- Reproductive potential Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
Exclusion Criteria:
- Patient has received any other investigational agents within 28 days of first day of study drug dosing.
- Patient with rapidly progressing disease may be enrolled before the 28 days period. In these cases, only the study chair can take this decision.
- Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria.
- Female patients who are pregnant or breast-feeding.
- Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection)
- Patient has a known brain metastasis. Non-specific central nervous system (CNS) changes on MRI/CT characteristic of NF1 are allowed, but not known CNS malignancies.
- Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
- Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.
- Patient received chemotherapy within 4 weeks prior to study entry.
- Patient previously received radiotherapy to greater than or equal to 25% of the bone marrow within 24 months.
- Patient had a major surgery within 2 weeks prior to study entry.
- Patient with any significant history of non-compliance to medical regimens.
- Patients who have or anticipate receiving permanent (or semi-permanent) metallic structures attached to their body. (e.g., braces on teeth, body piercings), which their physicians believe will interfere with the MRI.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Imatinib Mesylate
Imatinib Mesylate at 110 mg/m2 up to 440mg/m2 PO per day for twelve months taken in one morning dose (if dose is less than 200 mg/day) or two doses (morning and evening)
|
oral administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demonstrate the clinical benefit of imatinib in a pediatric patient population with progressing and metabolically active plexiform NFs
Time Frame: 12 months
|
Time to tumor progression as assessed by volumetric MRI and FDG-PETScan analysis at baseline, after 3, 6, 9, and 12 months on therapy.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in NF1 biomarkers after treatment with imatinib
Time Frame: 12 months
|
Patients on imatinib will have blood samples and urine taken at baseline and every 3 months until treatment completion or until disease progression.
Mastocyte activation biomarkers will be monitored and evaluated as potential disease state indicators.
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate trough plasma levels of imatinib and its active metabolite (NDMIL N-desmethyl imatinib) achieved in this pediatric population
Time Frame: 12 months
|
We will evaluate trough plasma levels of imatinib achieved in this patient population at 3, 6, 9 and 12 month and correlate it with response to treatment
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sébastien Perreault, MD/FRCPC, St. Justine's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Genetic Diseases, Inborn
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neoplasms, Nerve Tissue
- Peripheral Nervous System Diseases
- Nervous System Neoplasms
- Heredodegenerative Disorders, Nervous System
- Neoplastic Syndromes, Hereditary
- Nerve Sheath Neoplasms
- Neurocutaneous Syndromes
- Peripheral Nervous System Neoplasms
- Neurofibromatoses
- Neurofibromatosis 1
- Neurofibroma
- Neurofibroma, Plexiform
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Imatinib Mesylate
Other Study ID Numbers
- PLNEU SJ 01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plexiform Neurofibromas
-
National Cancer Institute (NCI)Active, not recruitingNeurofibromatosis 1 (NF1) | Plexiform Neurofibromas (PN)United States
-
AstraZenecaApproved for marketingNF type1 With Inoperable Plexiform NeurofibromasUnited States
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Neoplasm of Uncertain Malignant PotentialUnited States
-
SpringWorks Therapeutics, Inc.AvailableNeurofibromatosis Type 1-Associated Plexiform Neurofibromas | Histiocytic Neoplasm | Other MAP-K Pathway Driven Diseases
-
Shanghai Fosun Pharmaceutical Industrial Development...RecruitingNeurofibromatosis 1 | NF1 | Plexiform NeurofibromaChina
-
AstraZenecaMerck Sharp & Dohme LLCActive, not recruitingNeurofibromatosis 1 | Plexiform Neurofibroma (PN)United States, Canada, France, Italy, Germany, China, United Kingdom, Spain, Japan, Russian Federation, Australia, Poland, Brazil
-
AstraZenecaCompletedHealthy Participants | Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)United States
-
University of PittsburghNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)CompletedPlexiform Neurofibroma | Neurofibromatosis Type IUnited States
-
University of Alabama at BirminghamChildren's Hospital of Philadelphia; Congressionally Directed Medical Research...Not yet recruitingNeurofibromatosis 1 | Plexiform Neurofibroma
Clinical Trials on Imatinib Mesylate
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedChronic Myeloid LeukemiaChina
-
Scandinavian Sarcoma GroupCompleted
-
Institut BergoniéNovartisTerminatedLeukemia, Myeloid, Chronic-PhaseFrance
-
Sarit AssoulineNovartisRecruitingChronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | Chronic Myeloid Leukemia, BCR/ABL-PositiveCanada
-
University Health Network, TorontoNational Cancer Institute (NCI)CompletedHead and Neck CancerUnited States, Canada
-
NovartisCompletedLeukemiaUnited States
-
National Cancer Institute (NCI)CompletedSarcoma | Childhood Malignant Fibrous Histiocytoma of BoneUnited States
-
European Organisation for Research and Treatment...CompletedSarcoma | Small Intestine Cancer | Ovarian Cancer | Endometrial Cancer | Gastrointestinal Stromal TumorFrance, Denmark, Netherlands, Belgium, United Kingdom
-
Poitiers University HospitalNovartis; Roche Pharma AG; Ministry of Health, FranceCompleted
-
European Organisation for Research and Treatment...UNICANCER; Grupo Espanol de Investigacion en Sarcomas; Italian Sarcoma GroupCompletedGastrointestinal Stromal TumorFrance, Australia, United Kingdom, Germany, Denmark, Spain